Efficacy and tolerability of a low dose weekly paclitaxel, carboplatin and cetuximab (PCC) regimen for metastatic or unresectable head and neck squamous cell carcinomas

被引：0
|
作者：
Locke, Margaret [1 ,4 ]
Kohn, Nina [2 ]
Seetharamu, Nagashree [3 ]
机构：
[1] Zucker Sch Med Hofstra Northwell, Dept Internal Med, Manhasset, NY USA
[2] Northwell Hlth, Off Acad Affairs, Manhasset, NY USA
[3] Northwell Hlth, Monter Canc Ctr, Manhasset, NY USA
[4] 300 Community Dr, Manhasset, NY 11030 USA
来源：
CLINICAL OTOLARYNGOLOGY | 2023年 / 48卷 / 06期
关键词：
chemotoxicity; head and neck cancer; metastatic disease; unresectable head and neck cancer; CHEMOTHERAPY; RECURRENT;
D O I：
10.1111/coa.14091
中图分类号：
R76 [耳鼻咽喉科学];
学科分类号：
100213 ;
摘要：
引用
收藏
页码：915 / 919
页数：5
相关论文
共 50 条
  • [1] Efficacy and tolerability of a low dose weekly paclitaxel, carboplatin, cetuximab (PCC) regimen for metastatic or unresectable head and neck squamous cell carcinomas.
    Locke, Margaret
    Kohn, Nina
    Seetharamu, Nagashree
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E18019 - E18019
  • [2] Weekly Cetuximab and Paclitaxel for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
    Fushimi, Chihiro
    Baba, Daisuke
    Masubuchi, Tatsuo
    Yamazaki, Morio
    Kitani, Yosuke
    Kitajima, Tatsuya
    Tanaka, Junpei
    Hanyu, Kenji
    Tanaka, Naruhisa
    Miura, Kouki
    Tada, Yuichiro
    IN VIVO, 2020, 34 (05): : 2653 - 2657
  • [3] Weekly vs. 3-weekly paclitaxel, carboplatin, and cetuximab (PCC) in recurrent/metastatic head and neck cancer
    Geraghty, Leeann
    Schultz, Thomas E.
    Hoffman, Sarah E.
    Porter, Kyle
    Issa, Majd
    Karivedu, Vidhya
    Bonomi, Marcelo
    MOLECULAR AND CLINICAL ONCOLOGY, 2021, 15 (05)
  • [4] A comparison of weekly paclitaxel and cetuximab with the EXTREME regimen in the treatment of recurrent/metastatic squamous cell head and neck carcinoma
    Nakano, Kenji
    Marshall, Shoko
    Taira, Shinichiro
    Sato, Yukiko
    Tomomatsu, Junichi
    Sasaki, Toru
    Shimbashi, Wataru
    Fukushima, Hirofumi
    Yonekawa, Hiroyuki
    Mitani, Hiroki
    Kawabata, Kazuyoshi
    Takahashi, Shunji
    ORAL ONCOLOGY, 2017, 73 : 21 - 26
  • [5] Induction chemotherapy (CT) with weekly paclitaxel, carboplatin, and cetuximab for squamous cell carcinoma of the head and neck (HN).
    Kies, M. S.
    Garden, A. S.
    Holsinger, C.
    Papadimitrakopoulou, V.
    El-Naggar, A. K.
    Gillaspy, K.
    Lewin, J.
    Lu, C.
    Villalobos, S.
    Glisson, B. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 285S - 285S
  • [6] WEEKLY REGIMEN OF PACLITAXEL-CARBOPLATIN-CETUXIMAB IN PATIENTS WITH RECURRENT SQUAMOUS CELL CARCINOMA OF HEAD AND NECK (SCCNH): RESULTS OF A MONOCENTRIC EXPERIENCE
    Rozzi, A.
    Corona, M.
    Nardoni, C.
    Restuccia, M. R.
    Lanzetta, G.
    ANNALS OF ONCOLOGY, 2009, 20 : 44 - 44
  • [7] Clinical impact of weekly paclitaxel plus cetuximab is comparable to the EXTREME regimen for recurrent/metastatic head and neck squamous cell carcinoma
    Motai, Risa
    Sawabe, Michi
    Kadowaki, Shigenori
    Sasaki, Eiichi
    Nishikawa, Daisuke
    Suzuki, Hidenori
    Beppu, Shintaro
    Terada, Hoshino
    Hanai, Nobuhiro
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (07) : 1188 - 1195
  • [8] Clinical impact of weekly paclitaxel plus cetuximab is comparable to the EXTREME regimen for recurrent/metastatic head and neck squamous cell carcinoma
    Risa Motai
    Michi Sawabe
    Shigenori Kadowaki
    Eiichi Sasaki
    Daisuke Nishikawa
    Hidenori Suzuki
    Shintaro Beppu
    Hoshino Terada
    Nobuhiro Hanai
    International Journal of Clinical Oncology, 2021, 26 : 1188 - 1195
  • [9] Predictors of outcome in patients with recurrent/metastatic head and neck squamous cell carcinomas (RMHNSCC) treated with weekly cetuximab and paclitaxel (CP).
    Ferreira, Bruna Pellini
    Baker, Kelsey K.
    Redman, Mary
    Martins, Renato
    Eaton, Keith D.
    Chow, Laura Quan Man
    Baik, Christina S.
    Goulart, Bernardo
    Lee, Sylvia Mina
    Santana-Davila, Rafael
    Rodriguez, Cristina P.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [10] Phase II trial of carboplatin/paclitaxel and cetuximab, followed by carboplatin/paclitaxel/cetuximab and erlotinib, in metastatic or recurrent squamous cell carcinoma of the head and neck.
    Bhatia, Aarti K.
    Mehra, Ranee
    Khan, Saad A.
    Egleston, Brian L.
    Alpaugh, R. Katherine
    Lango, Miriam
    Ridge, John A.
    Burtness, Barbara
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345